Keynote-045: updated 3 years results by Andrea Necchi
Phase 2 TROPHY-U-01 open-label study of patients receiving sacituzumab-govitecan with metastatic urothelial cancer after failure of platinum-based regimens or immunotherapy by Scott Tagawa
Keynote-057 study: interim analysis
NEMIO trial by Stéphane Oudard
Overview on Keynote 57: "Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)"
Commentary on ESOU19 webcast "Is en-bloc TUR the best staging tool?"
Prostate sparing approaches
Lessons learned from the POUT trial: adjuvant chemotherapy does improve the outcomes of patients treated with RNU for UTUC
2018 Nov 10
ESMO/EAU consensus project in muscle invasive or metastatic bladder cancer report at EMUC 2018 by Prof. Witjes
Metastatic muscle invasive bladder cancer: When should immunotherapy be used? EMUC 2018 by Prof Bamias
2018 Nov 09
Editorial on RAZOR trial by Dr. Evanguelos Xylinas
Lancet. 2018 Jun 23